144 related articles for article (PubMed ID: 21864802)
1. Photobleaching-based method to individualize irradiation time during interstitial 5-aminolevulinic acid photodynamic therapy.
Hennig G; Stepp H; Johansson A
Photodiagnosis Photodyn Ther; 2011 Sep; 8(3):275-81. PubMed ID: 21864802
[TBL] [Abstract][Full Text] [Related]
2. Protoporphyrin IX fluorescence and photobleaching during interstitial photodynamic therapy of malignant gliomas for early treatment prognosis.
Johansson A; Faber F; Kniebühler G; Stepp H; Sroka R; Egensperger R; Beyer W; Kreth FW
Lasers Surg Med; 2013 Apr; 45(4):225-34. PubMed ID: 23533060
[TBL] [Abstract][Full Text] [Related]
3. Singlet oxygen model evaluation of interstitial photodynamic therapy with 5-aminolevulinic acid for malignant brain tumor.
Izumoto A; Nishimura T; Hazama H; Ikeda N; Kajimoto Y; Awazu K
J Biomed Opt; 2019 Dec; 25(6):1-13. PubMed ID: 31838789
[TBL] [Abstract][Full Text] [Related]
4. Interstitial photodynamic therapy of nonresectable malignant glioma recurrences using 5-aminolevulinic acid induced protoporphyrin IX.
Beck TJ; Kreth FW; Beyer W; Mehrkens JH; Obermeier A; Stepp H; Stummer W; Baumgartner R
Lasers Surg Med; 2007 Jun; 39(5):386-93. PubMed ID: 17565715
[TBL] [Abstract][Full Text] [Related]
5. Protoporphyrin IX fluorescence photobleaching and the response of rat Barrett's esophagus following 5-aminolevulinic acid photodynamic therapy.
Boere IA; Robinson DJ; de Bruijn HS; Kluin J; Tilanus HW; Sterenborg HJ; de Bruin RW
Photochem Photobiol; 2006; 82(6):1638-44. PubMed ID: 16879035
[TBL] [Abstract][Full Text] [Related]
6. Smartphone fluorescence imager for quantitative dosimetry of protoporphyrin-IX-based photodynamic therapy in skin.
Ruiz AJ; LaRochelle EPM; Gunn JR; Hull SM; Hasan T; Chapman MS; Pogue BW
J Biomed Opt; 2019 Dec; 25(6):1-13. PubMed ID: 31820594
[No Abstract] [Full Text] [Related]
7. Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas.
Cottrell WJ; Paquette AD; Keymel KR; Foster TH; Oseroff AR
Clin Cancer Res; 2008 Jul; 14(14):4475-83. PubMed ID: 18628462
[TBL] [Abstract][Full Text] [Related]
8. Protoporphyrin IX photobleaching during the light irradiation phase of standard dermatological methyl-aminolevulinate photodynamic therapy.
Tyrrell J; Campbell S; Curnow A
Photodiagnosis Photodyn Ther; 2010 Dec; 7(4):232-8. PubMed ID: 21112545
[TBL] [Abstract][Full Text] [Related]
9. The relationship between protoporphyrin IX photobleaching during real-time dermatological methyl-aminolevulinate photodynamic therapy (MAL-PDT) and subsequent clinical outcome.
Tyrrell JS; Campbell SM; Curnow A
Lasers Surg Med; 2010 Sep; 42(7):613-9. PubMed ID: 20806386
[TBL] [Abstract][Full Text] [Related]
10. In vitro percutaneous absorption and in vivo protoporphyrin IX accumulation in skin and tumors after topical 5-aminolevulinic acid application with enhancement using an erbium:YAG laser.
Shen SC; Lee WR; Fang YP; Hu CH; Fang JY
J Pharm Sci; 2006 Apr; 95(4):929-38. PubMed ID: 16493590
[TBL] [Abstract][Full Text] [Related]
11. Relation between intracellular location and photodynamic efficacy of 5-aminolevulinic acid-induced protoporphyrin IX in vitro. Comparison between human glioblastoma cells and other cancer cell lines.
Sailer R; Strauss WS; Wagner M; Emmert H; Schneckenburger H
Photochem Photobiol Sci; 2007 Feb; 6(2):145-51. PubMed ID: 17277837
[TBL] [Abstract][Full Text] [Related]
12. PpIX fluorescence kinetics and increased skin damage after intracutaneous injection of 5-aminolevulinic acid and repeated illumination.
Thissen MR; de Blois MW; Robinson DJ; de Bruijn HS; Dutrieux RP; Star WM; Neumann HA
J Invest Dermatol; 2002 Feb; 118(2):239-45. PubMed ID: 11841539
[TBL] [Abstract][Full Text] [Related]
13. A dynamic model for ALA-PDT of skin: simulation of temporal and spatial distributions of ground-state oxygen, photosensitizer and singlet oxygen.
Liu B; Farrell TJ; Patterson MS
Phys Med Biol; 2010 Oct; 55(19):5913-32. PubMed ID: 20844331
[TBL] [Abstract][Full Text] [Related]
14. 5-Aminolevulinic acid-based photodynamic detection and therapy of brain tumors (review).
Friesen SA; Hjortland GO; Madsen SJ; Hirschberg H; Engebraten O; Nesland JM; Peng Q
Int J Oncol; 2002 Sep; 21(3):577-82. PubMed ID: 12168102
[TBL] [Abstract][Full Text] [Related]
15. Is interstitial photodynamic therapy for brain tumors ready for clinical practice? A systematic review.
Leroy HA; Guérin L; Lecomte F; Baert G; Vignion AS; Mordon S; Reyns N
Photodiagnosis Photodyn Ther; 2021 Dec; 36():102492. PubMed ID: 34419674
[TBL] [Abstract][Full Text] [Related]
16. Monitoring the accumulation and dissipation of the photosensitizer protoporphyrin IX during standard dermatological methyl-aminolevulinate photodynamic therapy utilizing non-invasive fluorescence imaging and quantification.
Tyrrell J; Campbell SM; Curnow A
Photodiagnosis Photodyn Ther; 2011 Mar; 8(1):30-8. PubMed ID: 21333932
[TBL] [Abstract][Full Text] [Related]
17. Influence of administration methods on the accumulation of ALA-induced Pp-IX in mouse tongue tumors.
Ogasawara T; Miyoshi N; Sano K; Kitagawa Y; Yamada T; Ogawa T; Miyauchi K; Kinoshita H
Oral Dis; 2006 Jul; 12(4):415-9. PubMed ID: 16792728
[TBL] [Abstract][Full Text] [Related]
18. A quantitative comparison of 5-aminolaevulinic acid- and methyl aminolevulinate-induced fluorescence, photobleaching and pain during photodynamic therapy.
Valentine RM; Ibbotson SH; Brown CT; Wood K; Moseley H
Photochem Photobiol; 2011; 87(1):242-9. PubMed ID: 21077899
[TBL] [Abstract][Full Text] [Related]
19. Fluorescence photobleaching of ALA-induced protoporphyrin IX during photodynamic therapy of normal hairless mouse skin: the effect of light dose and irradiance and the resulting biological effect.
Robinson DJ; de Bruijn HS; van der Veen N; Stringer MR; Brown SB; Star WM
Photochem Photobiol; 1998 Jan; 67(1):140-9. PubMed ID: 9477772
[TBL] [Abstract][Full Text] [Related]
20. Increased fluorescence observation intensity during the photodynamic diagnosis of deeply located tumors by fluorescence photoswitching of protoporphyrin IX.
Ogbonna SJ; York WY; Nishimura T; Hazama H; Fukuhara H; Inoue K; Awazu K
J Biomed Opt; 2023 May; 28(5):055001. PubMed ID: 37197689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
